Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19

Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19

US Patent 11389481 · Granted Jul 19, 2022

Estimated economic value: $84,319,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Matrix metalloprotease-cleavable and serine protease-cleavable substrates and me2025
Genetically engineered T cells having improved persistence in culture2025
Genetically engineered T cells having improved persistence in culture2025
T-cells expressing anti-LIV1 chimeric antigen receptor2025
Methods and compositions for treating cancer2025
Methods and compositions for treating cancer2025
CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and use2024
CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and use2024
Anti-PTK7 immune cell cancer therapy2024
Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related cond2024
Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK2024
Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have imp2024